These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 25339667)

  • 1. Adoptive immunotherapy of epithelial ovarian cancer with Vγ9Vδ2 T cells, potentiated by liposomal alendronic acid.
    Parente-Pereira AC; Shmeeda H; Whilding LM; Zambirinis CP; Foster J; van der Stegen SJ; Beatson R; Zabinski T; Brewig N; Sosabowski JK; Mather S; Ghaem-Maghami S; Gabizon A; Maher J
    J Immunol; 2014 Dec; 193(11):5557-66. PubMed ID: 25339667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro potency, in vitro and in vivo efficacy of liposomal alendronate in combination with γδ T cell immunotherapy in mice.
    Hodgins NO; Al-Jamal WT; Wang JT; Parente-Pereira AC; Liu M; Maher J; Al-Jamal KT
    J Control Release; 2016 Nov; 241():229-241. PubMed ID: 27664328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
    Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
    J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex Vivo Expanded Human Vγ9Vδ2 T-Cells Can Suppress Epithelial Ovarian Cancer Cell Growth.
    Mao TL; Miao CH; Liao YJ; Chen YJ; Yeh CY; Liu CL
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30845699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
    Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
    J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: A new approach.
    Dokouhaki P; Han M; Joe B; Li M; Johnston MR; Tsao MS; Zhang L
    Cancer Lett; 2010 Nov; 297(1):126-36. PubMed ID: 20537791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
    Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vivo PET Tracking of
    Man F; Lim L; Volpe A; Gabizon A; Shmeeda H; Draper B; Parente-Pereira AC; Maher J; Blower PJ; Fruhwirth GO; T M de Rosales R
    Mol Ther; 2019 Jan; 27(1):219-229. PubMed ID: 30429045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-21-mediated potentiation of antitumor cytolytic and proinflammatory responses of human V gamma 9V delta 2 T cells for adoptive immunotherapy.
    Thedrez A; Harly C; Morice A; Salot S; Bonneville M; Scotet E
    J Immunol; 2009 Mar; 182(6):3423-31. PubMed ID: 19265120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo.
    Kabelitz D; Wesch D; Pitters E; Zöller M
    J Immunol; 2004 Dec; 173(11):6767-76. PubMed ID: 15557170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
    Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
    Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin α or its immunoactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice.
    Voutsas IF; Pistamaltzian N; Tsiatas ML; Skopeliti M; Katsila T; Mavrothalassiti I; Spyrou S; Dimopoulos MA; Tsitsilonis OE; Bamias A
    Eur J Cancer; 2013 May; 49(7):1706-14. PubMed ID: 23276721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating in vitro and in vivo αvβ6 integrin receptor-targeting liposomal alendronate for combinatory γδ T cell immunotherapy.
    Hodgins NO; Al-Jamal WT; Wang JT; Klippstein R; Costa PM; Sosabowski JK; Marshall JF; Maher J; Al-Jamal KT
    J Control Release; 2017 Jun; 256():141-152. PubMed ID: 28432037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.
    Chekmasova AA; Rao TD; Nikhamin Y; Park KJ; Levine DA; Spriggs DR; Brentjens RJ
    Clin Cancer Res; 2010 Jul; 16(14):3594-606. PubMed ID: 20628030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alendronate liposomes for antitumor therapy: activation of γδ T cells and inhibition of tumor growth.
    Gutman D; Epstein-Barash H; Tsuriel M; Golomb G
    Adv Exp Med Biol; 2012; 733():165-79. PubMed ID: 22101722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
    Benzaïd I; Mönkkönen H; Bonnelye E; Mönkkönen J; Clézardin P
    Clin Cancer Res; 2012 Nov; 18(22):6249-59. PubMed ID: 23032740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
    Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
    Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo.
    Xu XJ; Song DG; Poussin M; Ye Q; Sharma P; Rodríguez-García A; Tang YM; Powell DJ
    Oncotarget; 2016 Dec; 7(50):82354-82368. PubMed ID: 27409425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nano-technology based carriers for nitrogen-containing bisphosphonates delivery as sensitisers of γδ T cells for anticancer immunotherapy.
    Hodgins NO; Wang JT; Al-Jamal KT
    Adv Drug Deliv Rev; 2017 May; 114():143-160. PubMed ID: 28694026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.